Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BYFrontiers in surgery

Factors influencing future liver remnant hypertrophy after portal vein embolization: a mini review.

  • Yuxuan Lu1,2
  • Hangcheng Liu1,2
  • Boyang Wu1,2
  • Canhong Xiang1,2
  • Jianping Zeng1,2
  • Quanyu Guo3
  • Hongwei Lu3
  • Shizhong Yang1,2
  • Jitao Wang1,2
  • Jiahong Dong1,2
  1. 1Hepato-Pancreato-Biliary Center, Beijing Tsinghua Changgung Hospital, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
  2. 2Research Unit of Precision Hepatobiliary Surgery Paradigm, Chinese Academy of Medical Sciences, Beijing, China.
  3. 3Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Read full textPDFDOICite

Abstract

Portal vein embolization (PVE) promotes future liver remnant (FLR) hypertrophy before major hepatectomy, but the response varies substantially among patients. This review summarizes determinants of post-PVE FLR hypertrophy to support preoperative risk stratification and individualized planning. Targeted searches of PubMed/MEDLINE, Web of Science, Scopus, Embase, and China National Knowledge Infrastructure (CNKI) through 26 August 2026 combined terms for PVE, liver regeneration or FLR hypertrophy, and predictors or associated factors. Reference lists and the authors' existing reference collection were also screened, and evidence was narratively synthesized across five domains. FLR hypertrophy reflects multiple interacting determinants. Advanced age, selected chemotherapy exposures, and liver fibrosis have been associated with weaker regenerative responses. Elevated inflammatory markers and biliary infection may impair hypertrophy, whereas adequate embolization extent and appropriate embolic material selection may improve the response. FLR hypertrophy after PVE is determined by interacting demographic and clinical, laboratory, hepatic and biliary, tumor-related, and procedure-related factors. Recognizing these determinants may improve patient selection, help predict insufficient hypertrophy, and guide individualized PVE strategies to increase the safety of major hepatectomy.

Related

  1. Echocardiographic Left Ventricular Hypertrophy Among Patients with Type 2 Diabetes Undergoing Clinically Indicated Echocardiography at a Saudi Cardiac Center: Prevalence and Associated Factors
    Jolan Alsaud, Mohammed Aldkheel, Fatimah Alenazi +8
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Preoperative HAIC enlarges future liver remnant in initial unresectable HCC patients with Vp3 tumor thrombus.
    Yifan Zhang, Yiquan Lu, Yuchen Yang +6
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  3. Analysis of High‐Risk Factors for Failure of Bleeding Control in Enhanced Myometrial Vascularity Treated With Uterine Artery Embolization
    Linhua Zhu, Yongfang Yue, Lili Cao
    Journal of Clinical UltrasoundPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsPMC
  4. Path Analysis of Factors Influencing Job Satisfaction Among Clinical Nurse Managers: A Cross‐Sectional Study
    Zhang WenXin, Liu Liping, Li Yue +1
    Health science reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Factors influencing baseline electrocardiographic parameters in rats: A systematic review of experimental studies published from 1960 to the present
    Viktória Novotná, Soňa Grešová, Pavol Švorc
    Physiological reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{lu2026factors,
  title = {{Factors influencing future liver remnant hypertrophy after portal vein embolization: a mini review.}},
  author = {Yuxuan Lu and Hangcheng Liu and Boyang Wu and Canhong Xiang and Jianping Zeng and Quanyu Guo and Hongwei Lu and Shizhong Yang and Jitao Wang and Jiahong Dong},
  journal = {Frontiers in surgery},
  year = {2026},
  month = oct,
  doi = {10.3389/fsurg.2026.1979361},
  url = {https://europepmc.org/article/MED/42952979},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Factors influencing future liver remnant hypertrophy after portal vein embolization: a mini review.
AU  - Yuxuan Lu
AU  - Hangcheng Liu
AU  - Boyang Wu
AU  - Canhong Xiang
AU  - Jianping Zeng
AU  - Quanyu Guo
AU  - Hongwei Lu
AU  - Shizhong Yang
AU  - Jitao Wang
AU  - Jiahong Dong
PY  - 2026
DA  - 2026/10/14
JO  - Frontiers in surgery
DO  - 10.3389/fsurg.2026.1979361
UR  - https://europepmc.org/article/MED/42952979
AB  - Portal vein embolization (PVE) promotes future liver remnant (FLR) hypertrophy before major hepatectomy, but the response varies substantially among patients. This review summarizes determinants of post-PVE FLR hypertrophy to support preoperative risk stratification and individualized planning. Targeted searches of PubMed/MEDLINE, Web of Science, Scopus, Embase, and China National Knowledge Infrastructure (CNKI) through 26 August 2026 combined terms for PVE, liver regeneration or FLR hypertrophy, and predictors or associated factors. Reference lists and the authors' existing reference collection were also screened, and evidence was narratively synthesized across five domains. FLR hypertrophy reflects multiple interacting determinants. Advanced age, selected chemotherapy exposures, and liver fibrosis have been associated with weaker regenerative responses. Elevated inflammatory markers and biliary infection may impair hypertrophy, whereas adequate embolization extent and appropriate embolic material selection may improve the response. FLR hypertrophy after PVE is determined by interacting demographic and clinical, laboratory, hepatic and biliary, tumor-related, and procedure-related factors. Recognizing these determinants may improve patient selection, help predict insufficient hypertrophy, and guide individualized PVE strategies to increase the safety of major hepatectomy.
SN  - 2296-875X
ER  -